ReviewNeuro-oncology practice2020
Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma.
Review in Neuro-oncology practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- MEK inhibition in adult patients with pilocytic astrocytomas.NPJ precision oncology · 2026Article
- Optic Pathway Glioma: Current Treatment Approaches and Ongoing Clinical Trials.Brain sciences · 2025Review
- MRI-based, three-dimensionally assessed tumor burden and growth velocity to predict visual acuity deterioration in optic pathway glioma - results of a retrospective longitudinal analysis.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025Article
- Exploring Optic Glioma and Type 1 Neurofibromatosis: A Literature Review of Case Reports.Neuro-ophthalmology (Aeolus Press) · 2025Review
- Disease burden and healthcare utilization in pediatric low-grade glioma: A United States retrospective study of linked claims and electronic health records.Neuro-oncology practice · 2024Article
- BRAF/MEK inhibitors use for pediatric gliomas; real world experience from a resource-limited country.Frontiers in oncology · 2024Article
- Optic Pathway Gliomas in Pediatric Population-Current Approach in Diagnosis and Management: Literature Review.Journal of clinical medicine · 2023Review
- Long-term treatment outcomes of pediatric low-grade gliomas treated at a university-based hospital.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2023Article
- Proton therapy for pediatric diencephalic tumors.Frontiers in oncology · 2023Review
- Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma.Neuro-oncology · 2022Article
- Neurosurgery for Optic Pathway Glioma: Optimizing Multidisciplinary Management.Frontiers in surgery · 2022Review
- Management of Inoperable Supra-Sellar Low-Grade Glioma With BRAF Mutation in Young Children.Cureus · 2021Article
- Response to Letter by Walker et al.Neuro-oncology practice · 2020Article
- Regarding "Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma".Neuro-oncology practice · 2020Article
- Letter to the Editor regarding clinical debate concerning treatment of pediatric LGG by Cooney et al.Neuro-oncology practice · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
The treatment of children with low-grade glioma has evolved over the last several decades, beginning initially with focal radiotherapy, which has now been largely replaced by systemic treatment with conventional chemotherapy agents or more recently molecularly targeted therapeutics. A consensus standard of care is not well defined, leaving clinicians and parents to choose from an increasing number of options, often without complete information concerning the associated risks and benefits. Issues critical to this topic include timing of interventions (when to treat), preservation of neurological function (goals of treatment), choice of initial therapy strategy (conventional cytotoxic chemotherapy vs molecularly targeted therapy), duration of treatment (how long, and what clinical or imaging endpoints to consider), and perhaps most important, risk reduction relative to anticipated benefit. The groups from the University of California, San Francisco and Dana Farber Cancer Institute, moderated by Michael Prados, herein debate the merits of cytotoxic chemotherapy and targeted therapeutics as initial treatment strategies in pediatric low-grade glioma, a topic discussed daily in Tumor Boards across the United States and abroad. Prospective, randomized, phase 3 trials comparing the 2 strategies, conducted within homogenous disease settings, with consistently evaluated functional and imaging endpoints, are not available to guide the risks/benefit discussion. As is often the case in rare biologically diverse diseases, in a vulnerable population, therapy decisions are frequently based on incomplete data, physician experience, bias to some degree, and patient/family preference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.